The Scottish Medicines Consortium has issued its monthly advice on new medicines.
Vildagliptin in combination with metformin (Eucreas®) has been accepted for restricted use (PDF). The combination should be used in patients for whom monotherapy with metformin provides insufficient glycaemic control and where the addition of a sulphonylurea is not appropriate. In this instance the addition of vildagliptin is an alternative to using glitazones.
Fesoterodine fumarate (Toviaz®) has also been accepted for restricted use (PDF). The advice notes that this drug is equivalent to existing therapies in terms of efficacy and also has a typical adverse event profile. The higher acquisition cost restricts this new drug to second-line use.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« PMCPA Code of Practice update||Second FAD for osteoporosis guidance »|